drugset / Trial / NCT02315144

An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients

NCT02315144 ↗

Phase 1 Terminated 61 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of the study is to characterize the safety profile and duration of bronchodilation of a single dose of inhaled TV48108.

Timeline

Start
2015-04
Primary completion
2015-08
Completion
2015-08

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject TV48108 Unknown 15 ug Inhaled
Subject TV48108 Unknown 60 ug Inhaled
Subject TV48108 Unknown 120 ug Inhaled